{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031862","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.485986+00:00","generated_at":"2026-05-31T09:29:44.124824+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Abeona Therapeutics appoints Drs. Zeiher and Crombez to Board of Directors","bullets":["Bernhardt G. Zeiher, MD appointed as Class 1 director; Eric Crombez, MD as Class 2 director; both independent.","Zeiher is former CMO of Astellas Pharma with 20+ years of drug development; Crombez is CMO of Ultragenyx and FDA advisory committee member.","Each director receives $50,000 annual cash retainer and $55,000 one-time RSAs with one-year vesting.","Appointments effective August 8, 2024 (Zeiher) and August 12, 2024 (Crombez).","Additions come as Abeona focuses on pz-cel gene therapy for RDEB and pipeline expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031862","json":"https://secwatch.observer/filing/0001493152-24-031862.json","markdown":"https://secwatch.observer/filing/0001493152-24-031862.md","text":"https://secwatch.observer/filing/0001493152-24-031862.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315224031862/0001493152-24-031862-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315224031862/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:29:44.124824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"240c3b17dd","claim":"Eric Crombez was appointed as Director at ABEONA THERAPEUTICS INC..","evidence_excerpt":"appointed Bernhardt G. Zeiher, MD, FCCP, FACP, on August 8, 2024 and Eric Crombez, MD on August 12, 2024 as members of the Board of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224031862/0001493152-24-031862-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ff4977ec32","claim":"Bernhardt G. Zeiher was appointed as Director at ABEONA THERAPEUTICS INC..","evidence_excerpt":"appointed Bernhardt G. Zeiher, MD, FCCP, FACP, on August 8, 2024 and Eric Crombez, MD on August 12, 2024 as members of the Board of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224031862/0001493152-24-031862-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}